Mixed oxybate salts (calcium, magnesium, potassium, and sodium oxybates)

Mixed oxybate salts (calcium, magnesium, potassium, and sodium oxybates) is filed as Narcolepsy treatment. The sections below restate public label fields stored for this profile.

Class
Narcolepsy treatment
Generic name
calcium, magnesium, potassium, and sodium oxybates
Route
ORAL
Dosage forms
• CNS depression: Use caution when considering the concurrent use of XYWAV with other CNS depressants ( 5.1 ). • Caution patients against hazardous activities requiring complete mental alertness or motor coordination within the first 6 hours of dosing or after first initiating treatment until certain that XYWAV does not affect them adversely ( 5.1 ). • Depression and suicidality: Monitor patients for emergent or increased depression and suicidality ( 5.5 ). • Confusion/Anxiety: Monitor for impaired motor/cognitive function ( 5.6 ). • Parasomnias: Evaluate episodes of sleepwalking ( 5.7 ).
Manufacturer
Jazz Pharmaceuticals, Inc.
Boxed warning
Yes

Approved uses

XYWAV is a central nervous system depressant indicated for the treatment of: • Cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy ( 1.1 ). • Idiopathic Hypersomnia (IH) in adults ( 1.2 ).

How it works

XYWAV is a CNS depressant. The exact mechanism of action of XYWAV in the treatment of narcolepsy and idiopathic hypersomnia is unknown. XYWAV is a mixture of calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate (gamma-hydroxybutyrate). Gamma-hydroxybutyrate (GHB) is an endogenous compound and metabolite of the neurotransmitter GABA. It is hypothesized that the therapeutic effects of XYWAV are mediated through GABA B actions during sleep at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons.

Boxed warning

WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE. • Central Nervous System Depression XYWAV is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with XYWAV at recommended doses [see Warnings and Precautions ( 5.1 , 5.4 )]. Many patients who received XYWAV during clinical trials in narcolepsy and idiopathic hypersomnia were receiving central nervous system stimulants [see Clinical Studies ( 14.1 , 14.2 , 14.3 )]. • Abuse and Misuse The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions ( 5.2 )]. Because of the risks of CNS depression and abuse and misuse, XYWAV is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS [see Warnings and Precautions ( 5.3 )]. WARNING: CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION and ABUSE AND MISUSE. See full prescribing information for complete boxed warning. Central Nervous System Depression • XYWAV is a CNS depressant, and respiratory depression can occur with XYWAV use ( 5.1 , 5.4 ) Abuse and Misuse • The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB is associated with CNS adverse reactions, including seizure, respiratory depression, decreased consciousness, coma, and death ( 5.2 , 9.2 ) XYWAV is available only through a restricted program called the XYWAV and XYREM REMS ( 5.3 )

Warnings and precautions

BOXED WARNING: WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE. • Central Nervous System Depression XYWAV is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with XYWAV at recommended doses [see Warnings and Precautions ( 5.1 , 5.4 )]. Many patients who received XYWAV during clinical trials in narcolepsy and idiopathic hypersomnia were receiving central nervous system stimulants [see Clinical Studies ( 14.1 , 14.2 , 14.3 )]. • Abuse and Misuse The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions ( 5.2 )]. Because of the risks of CNS depression and abuse and misuse, XYWAV is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS [see Warnings and Precautions ( 5.3 )]. WARNING: CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION and ABUSE AND MISUSE. See full prescribing information for complete boxed warning. Central Nervous System Depression • XYWAV is a CNS depressant, and respiratory depression can occur with XYWAV use ( 5.1 , 5.4 ) Abuse and Misuse • The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB is associated with CNS adverse reactions, including seizure, respiratory depression, decreased consciousness, coma, and death ( 5.2 , 9.2 ) XYWAV is available only through a restricted program called the XYWAV and XYREM REMS ( 5.3 )

Contraindications

XYWAV is contraindicated for use in: • combination with sedative hypnotics [see Warnings and Precautions ( 5.1 )] . • combination with alcohol [see Warnings and Precautions ( 5.1 , 5.2 )] . • patients with succinic semialdehyde dehydrogenase deficiency [see Clinical Pharmacology ( 12.3 )] .

Common side effects

Reactions in adults with narcolepsy or ih (≥5%); The most common adverse reactions (≥5%); Patients (4%); Ion leading to discontinuation was nausea (1.5%); L trial the most common adverse reactions (≥5%); Were nausea (20%); Enuresis (19%); Vomiting (18%)

Adverse reactions

The following clinically significant adverse reactions appear in other sections of the labeling: • CNS depression [see Warnings and Precautions ( 5.1 )] • Abuse and Misuse [see Warnings and Precautions ( 5.2 )] • Respiratory Depression and Sleep-Disordered Breathing [see Warnings and Precautions ( 5.4 )] • Depression and Suicidality [see Warnings and Precautions ( 5.5 )] • Other Behavioral or Psychiatric Adverse Reactions [see Warnings and Precautions ( 5.6 )] • Parasomnias [see Warnings and Precautions ( 5.7 )]

Dosage and administration

See Full Prescribing Information for complete dosing instructions ( 2.1 - 2.7 ). Dosage for Adult Patients with Narcolepsy • Initiate dosage at 4.5 g per night orally, divided into two doses ( 2.1 ). • Titrate to effect in increments of up to 1.5 g per night per week ( 2.1 ). • Recommended dosage range: 6 g to 9 g per night orally, divided into two doses ( 2.1 ). • Doses may be divided equally or unequally and the first dose taken at bedtime and the second dose taken 2.5 to 4 hours later ( 2.1 ). Dosage for Pediatric Patients with Narcolepsy (7 Years of Age and Older) • The recommended starting dosage, titration regimen, and maximum total nightly dosage are based on body weight (2.2 ). Dosage for Adult Patients with Idiopathic Hypersomnia • XYWAV can be administered as a twice or once nightly regimen in adults ( 2.3 ). • Twice nightly: Initiate dosage at 4.5 g or less per night orally, divided into two doses. Titrate to effect in increments of up to 1.5 g per night per week, up to 9 g total nightly dose ( 2.3 ). • Once nightly: Initiate dosage at 3 g or less per night orally, as one dose. Titrate to effect in increments of up to 1.5 g per night per week, up to 6 g total nightly dose ( 2.3 ). Important Administration Information • Administer XYWAV at least 2 hours after eating ( 2.4 ). • Prepare XYWAV prior to bedtime; dilute with approximately ¼ cup of water in pharmacy-provided containers ( 2.4 ). • Take XYWAV while in bed and lie down after dosing ( 2.4 ). For Patients Transitioning from Xyrem to XYWAV: Initiate at the same dose and regimen as Xyrem (gram for gram). Titrate as needed based on efficacy and tolerability ( 2.5 ). Patients with Hepatic Impairment Recommended starting dosage is one-half of the original dosage per night administered orally, divided into two doses ( 2.6 ).

Drug interactions

Concomitant use with divalproex sodium: An initial reduction in XYWAV dose of at least 20% is recommended ( 2.7 , 7.2 ).

Common questions

What is Mixed oxybate salts approved to treat?

According to its FDA label, Mixed oxybate salts (calcium, magnesium, potassium, and sodium oxybates) is approved for: XYWAV is a central nervous system depressant indicated for the treatment of: • Cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy ( 1.1 ). • Idiopathic Hypersomnia (IH) in adults ( 1.2 ). For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Mixed oxybate salts?

Mixed oxybate salts (calcium, magnesium, potassium, and sodium oxybates) belongs to the Narcolepsy treatment class of medications.

What form does Mixed oxybate salts come in?

The FDA label lists Mixed oxybate salts (calcium, magnesium, potassium, and sodium oxybates) as: CNS depression: Use caution when considering the concurrent use of XYWAV with other CNS depressants ( 5.1 ). • Caution patients against hazardous activities requiring complete mental alertness or motor coordination within the first 6 hours of dosing or after first initiating treatment until certain that XYWAV does not affect them adversely ( 5.1 ). • Depression and suicidality: Monitor patients for emergent or increased depression and suicidality ( 5.5 ). • Confusion/Anxiety: Monitor for impaired motor/cognitive function ( 5.6 ). • Parasomnias: Evaluate episodes of sleepwalking ( 5.7 ).; oral route. Available strengths and packaging vary by manufacturer.

Does Mixed oxybate salts have a Boxed Warning?

Yes. The FDA label for Mixed oxybate salts (calcium, magnesium, potassium, and sodium oxybates) carries a Boxed Warning. Excerpt: "WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE. • Central Nervous System Depression XYWAV is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated…" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.

Is Mixed oxybate salts currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Mixed oxybate salts (calcium, magnesium, potassium, and sodium oxybates) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Mixed oxybate salts approved by the FDA?

The FDA record lists the approval date for Mixed oxybate salts (calcium, magnesium, potassium, and sodium oxybates) as 2020-07-21.

Who makes Mixed oxybate salts?

The FDA label lists Jazz Pharmaceuticals, Inc. as a labeler/manufacturer of Mixed oxybate salts (calcium, magnesium, potassium, and sodium oxybates). Multiple firms may market generics of the same molecule.

How should Mixed oxybate salts be stored?

The FDA label states: "XYWAV is a clear to slightly opalescent oral solution. Each prescription includes at least one bottle of XYWAV with attached press in bottle adaptor, an oral measuring device (plastic syringe), and a Medication Guide. Th…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…